[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

DK0625053T3 - Urease-baseret vaccine mod Helicobacter-infektion - Google Patents

Urease-baseret vaccine mod Helicobacter-infektion

Info

Publication number
DK0625053T3
DK0625053T3 DK94900794T DK94900794T DK0625053T3 DK 0625053 T3 DK0625053 T3 DK 0625053T3 DK 94900794 T DK94900794 T DK 94900794T DK 94900794 T DK94900794 T DK 94900794T DK 0625053 T3 DK0625053 T3 DK 0625053T3
Authority
DK
Denmark
Prior art keywords
urease
vaccine against
based vaccine
helicobacter infection
against helicobacter
Prior art date
Application number
DK94900794T
Other languages
Danish (da)
English (en)
Inventor
Pierre Michetti
Andre Blum
Catherine Davin
Rainer Max Planck Institu Haas
Irene Corthesy-Theulaz
Jean-Pierre Kraehenbuhl
Emilia Saraga
Original Assignee
Oravax Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25517797&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0625053(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oravax Inc filed Critical Oravax Inc
Application granted granted Critical
Publication of DK0625053T3 publication Critical patent/DK0625053T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94900794T 1992-11-03 1993-11-02 Urease-baseret vaccine mod Helicobacter-infektion DK0625053T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97099692A 1992-11-03 1992-11-03
US08/085,938 US5972336A (en) 1992-11-03 1993-07-06 Urease-based vaccine against helicobacter infection
PCT/EP1993/003059 WO1994009823A1 (en) 1992-11-03 1993-11-02 Urease-based vaccine against helicobacter infection

Publications (1)

Publication Number Publication Date
DK0625053T3 true DK0625053T3 (da) 2002-08-12

Family

ID=25517797

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94900794T DK0625053T3 (da) 1992-11-03 1993-11-02 Urease-baseret vaccine mod Helicobacter-infektion

Country Status (29)

Country Link
US (1) US5972336A (pt)
EP (2) EP0625053B1 (pt)
JP (1) JPH07503255A (pt)
KR (1) KR100287424B1 (pt)
CN (1) CN1111429C (pt)
AT (1) ATE217196T1 (pt)
AU (2) AU678195C (pt)
BR (1) BR9305711A (pt)
CA (1) CA2127283A1 (pt)
CZ (1) CZ284416B6 (pt)
DE (1) DE69331901T2 (pt)
DK (1) DK0625053T3 (pt)
ES (1) ES2176232T3 (pt)
FI (1) FI112032B (pt)
GE (1) GEP20012429B (pt)
HU (1) HU219760B (pt)
IL (1) IL107474A (pt)
MX (1) MX9306841A (pt)
NO (1) NO942490L (pt)
NZ (2) NZ258118A (pt)
OA (1) OA10087A (pt)
PL (1) PL174448B1 (pt)
PT (1) PT625053E (pt)
RO (1) RO114870B1 (pt)
RU (1) RU2125891C1 (pt)
SG (1) SG70978A1 (pt)
SK (1) SK280619B6 (pt)
WO (1) WO1994009823A1 (pt)
ZA (1) ZA938203B (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US6290962B1 (en) * 1992-11-03 2001-09-18 Oravax, Inc. Urease-based vaccine and treatment for helicobacter infection
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
WO1995014093A1 (en) 1993-05-19 1995-05-26 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions and nucleic acid sequences encoding said polypeptides
US6406703B1 (en) 1993-07-27 2002-06-18 Csl Limited Treatment of H. pylori associated gastroduodenal disease
US5871749A (en) * 1993-07-27 1999-02-16 Csl Limited Therapeutic treatment of H. pylori associated gastroduodenal disease
AUPM612494A0 (en) 1994-06-08 1994-06-30 Csl Limited Treatment or prevention of helicobacter infection
AU702878B2 (en) * 1994-06-08 1999-03-11 Csl Limited Treatment and prevention of helicobacter infection
CA2194236C (en) * 1994-07-01 2009-02-24 Dermot Kelleher Helicobacter proteins and vaccines
CZ342697A3 (cs) * 1995-04-28 1998-06-17 Oravax, Inc. Multimerní rekombinantní ureázová vakcina
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine
EP0840796A2 (en) * 1995-07-26 1998-05-13 Maxim Pharmaceuticals Mucosal delivery of polynucleotides
GB2307987A (en) * 1995-12-06 1997-06-11 Univ Manchester Epitopes of the urease of Helicobacter pylori as dignostic agents; pharmaceuticals comprising such epitopes or the antibodies thereto
US6248551B1 (en) * 1997-03-28 2001-06-19 Institut Pasteur Helicobacter aliphatic amidase AmiE polypeptides, and DNA sequences encoding those polypeptides
US20020026035A1 (en) * 1997-04-01 2002-02-28 Harold Kleanthous Helicobacter ghpo 1360 and ghpo 750 polypeptides and corresponding polynucleotide molecules
AU7537598A (en) * 1997-04-30 1998-11-24 Pasteur Merieux Serums Et Vaccins Dna based anti-(helicobacter) vaccine composition
US20030158396A1 (en) * 1997-07-29 2003-08-21 Harold Kleanthous Identification of polynucleotides encoding novel helicobacter polypeptides in the helicobacter genome
US5985631A (en) 1997-09-12 1999-11-16 Oravax-Merieux Co. Method for preventing the activation of inactive, recombinant Helicobacter pylori apourease
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US20020151462A1 (en) * 1998-02-19 2002-10-17 Ling Lissolo Helicobacter pylori membrane proteins
GB9807721D0 (en) * 1998-04-08 1998-06-10 Chiron Spa Antigen
CN1323222A (zh) 1998-06-19 2001-11-21 梅里厄奥拉瓦克斯公司 Lt和ct以非肠道免疫法抗螺旋杆菌感染
US6190667B1 (en) * 1998-06-30 2001-02-20 Institut Pasteur Methods of inhibiting Helicobacter pylori
WO2000003730A1 (en) * 1998-07-16 2000-01-27 Cheil Jedang Corporation Urease based vaccine against helicobacter infection
ES2368987T3 (es) * 1999-02-05 2011-11-24 Alk-Abelló A/S Sistema de administración a través de las mucosas.
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
US20020107368A1 (en) * 2000-12-07 2002-08-08 Jing-Hui Tian Helicobacter proteins, gene sequences and uses thereof
AUPR524101A0 (en) * 2001-05-25 2001-06-21 Council Of The Queensland Institute Of Medical Research, The Antigen targeting
IL159210A0 (en) * 2001-06-07 2004-06-01 Wyeth Corp Mutant forms of cholera holotoxin as an adjuvant
JP2005508143A (ja) * 2001-06-07 2005-03-31 ワイス・ホールデイングス・コーポレーシヨン アジュバントとしてのコレラホロトキシンの突然変異形
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
WO2006066089A1 (en) 2004-12-15 2006-06-22 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
CN100460014C (zh) * 2006-07-20 2009-02-11 中国人民解放军第三军医大学 基于尿素酶b亚单位活性片段的幽门螺杆菌疫苗及其制备方法
AU2007317206B2 (en) * 2006-11-10 2013-04-18 Ondek Pty Ltd Methods and devices for the delivery of peptides into the gastric mucosa
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
JP5889529B2 (ja) 2007-07-27 2016-03-22 ヤンセン・サイエンシズ・アイルランド・ユーシー アミロイド原性疾患の処置
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
KR100982489B1 (ko) * 2007-12-17 2010-09-15 대구한의대학교산학협력단 헬리코박터 파일로리로부터 유래된 항원을 이용하여헬리코박터 파일로리 특이 항체 생산을 위한 백신을제조하는 방법
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) * 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
PL218700B1 (pl) 2012-03-29 2015-01-30 Gdański Univ Medyczny Doustna szczepionka zawierająca przetrwalniki Bacillus subtilis oraz jej zastosowanie do immunizacji przeciwko Helicobacter pylori
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
EP2837939A1 (en) * 2013-08-13 2015-02-18 Technische Universität München Method for the detection of H.pylori infection
PT3065771T (pt) 2013-11-04 2019-06-24 Uti Lp Metodos e composicoes para imunoterapia prolongada
JP6920211B2 (ja) 2015-05-06 2021-08-18 ユーティーアイ リミテッド パートナーシップ 持続療法用のナノ粒子組成物

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879213A (en) * 1986-12-05 1989-11-07 Scripps Clinic And Research Foundation Synthetic polypeptides and antibodies related to Epstein-Barr virus early antigen-diffuse
US5268276A (en) * 1988-09-16 1993-12-07 Jan Holmgren Recombinant systems for expression of cholera B-sub-unit with the aid of foreign promoters and/or leader peptides
FR2637612B1 (fr) * 1988-10-06 1993-09-10 Pasteur Institut Sequences de nucleotides codant pour une proteine a activite ureasique
US5443832A (en) * 1990-04-16 1995-08-22 Institut Swisse De Recherches Experimentales Sur Le Cancer Hydroxyapatite-antigen conjugates and methods for generating a poly-Ig immune response
JPH04169539A (ja) * 1990-11-01 1992-06-17 Imuno Japan:Kk 消化器疾患治療・予防剤およびその製造方法
CA2109088A1 (en) * 1991-04-26 1992-10-27 Emanuel Calenoff Methods to detect and treat diseases caused by bacterial allergens
FR2682122B1 (fr) * 1991-10-03 1995-06-09 Pasteur Institut Nouveaux genes d'helicobacter pylori. leur utilisation pour la preparation de souches recombinantes de h. pylori.
US5859219A (en) * 1992-02-26 1999-01-12 Vanderbilt University Purified vacuolating toxin from Helicobacter pylori and methods to use same
AU3630093A (en) * 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
MX9301706A (es) * 1992-04-13 1994-05-31 Oravax Inc Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
US5733740A (en) * 1992-10-13 1998-03-31 Vanderbilt University Taga gene and methods for detecting predisposition to peptic ulceration and gastric carcinoma
US5843460A (en) * 1993-05-19 1998-12-01 Institut Pasteur Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides
US5681736A (en) * 1994-10-05 1997-10-28 Antex Biologics, Inc. Methods for producing enhanced antigenic shigella bacteria and vaccines comprising same
US5837240A (en) * 1995-04-28 1998-11-17 Oravax-Merieux Co. Multimeric, recombinant urease vaccine

Also Published As

Publication number Publication date
RO114870B1 (ro) 1999-08-30
NZ299149A (en) 1997-12-19
HUT69938A (en) 1995-09-28
KR100287424B1 (ko) 2001-04-16
US5972336A (en) 1999-10-26
OA10087A (en) 1996-12-18
AU678195B2 (en) 1997-05-22
BR9305711A (pt) 1997-02-18
FI943171A0 (fi) 1994-07-01
MX9306841A (es) 1995-01-31
CZ284416B6 (cs) 1998-11-11
IL107474A (en) 1998-09-24
SK79394A3 (en) 1996-09-04
WO1994009823A1 (en) 1994-05-11
PL174448B1 (pl) 1998-07-31
PL304419A1 (en) 1995-01-09
HU9402261D0 (en) 1994-10-28
ZA938203B (en) 1994-06-09
JPH07503255A (ja) 1995-04-06
EP0625053A1 (en) 1994-11-23
ES2176232T3 (es) 2002-12-01
CN1094640A (zh) 1994-11-09
AU678195C (en) 2003-06-12
NO942490D0 (no) 1994-07-01
SK280619B6 (sk) 2000-05-16
EP1170016A2 (en) 2002-01-09
FI943171A (fi) 1994-09-01
GEP20012429B (en) 2001-05-25
DE69331901D1 (de) 2002-06-13
IL107474A0 (en) 1994-02-27
CZ160994A3 (en) 1995-04-12
EP0625053B1 (en) 2002-05-08
AU5561994A (en) 1994-05-24
NZ258118A (en) 1997-04-24
ATE217196T1 (de) 2002-05-15
NO942490L (no) 1994-08-22
PT625053E (pt) 2002-09-30
RU2125891C1 (ru) 1999-02-10
HU219760B (hu) 2001-07-30
SG70978A1 (en) 2000-03-21
AU2003270987A1 (en) 2004-01-22
CN1111429C (zh) 2003-06-18
FI112032B (fi) 2003-10-31
CA2127283A1 (en) 1994-05-11
DE69331901T2 (de) 2002-10-31
EP1170016A3 (en) 2002-03-06

Similar Documents

Publication Publication Date Title
DK0625053T3 (da) Urease-baseret vaccine mod Helicobacter-infektion
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
ES2092306T3 (es) Adyuvante para vacunas.
MX9301706A (es) Composicion de vacuna para el tratamiento de la infeccion por helicobacter.
RU93058676A (ru) Оральное лечение геликобактерной инфекции
CH614718A5 (en) Process for the preparation of glucosamine derivatives
FI851859L (fi) Antigenpreparat och isolering av saodana preparat.
LU91595I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutinine filamenteuse, de pertactine et de polyoside capsulaire d'haemophilus influenzae type b (InfanrixHib)
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
NZ314585A (en) Method of treating H. Pylori associated gastroduodenal disease
NZ192477A (en) Method for protecting dogs against virulent canine parvovirus using inactivated virus vaccine
NO924271D0 (no) Vaksiner med forbedret immunogenisitet
SE9604322D0 (sv) Bacterial antigens and vaccine compositions II
PT757556E (pt) Bacterina borrelia burgdorferi
NO913131L (no) Immunogene konjugater av ikke-toksisk oligosakkarid fra bordetella pertussis lipoolysakkarid.
FR2646776B1 (fr) Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
FI971402A0 (fi) Menetelmä voimistettujen antigeenisten Helico-bacter-lajien ja niitä sisältävien rokotteiden valmistamiseksi
DK52783A (da) Vaccine indeholdende en ozon-inaktiveret mikroorganisme og fremgangsmaade til fremstilling af en saadan vaccine
ES515472A0 (es) Procedimiento para proteger anfitriones susceptibles de infeccion de hepatitis.
NO934547L (no) Oral behandling av Helicobacter-infeksjon
MX9604262A (es) Antigenos de pasteurellaceae y vacunas relacionadas.